Medicare Program; Meeting Announcement for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests, 23084-23085 [2023-07913]

Download as PDF 23084 Federal Register / Vol. 88, No. 72 / Friday, April 14, 2023 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–1797–N] Medicare Program; Meeting Announcement for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice. AGENCY: This notice announces the public meeting dates for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the Panel) on Wednesday, July 19, 2023 and Thursday, July 20, 2023. The purpose of the Panel is to advise the Secretary of the Department of Health and Human Services and the Administrator of the Centers for Medicare & Medicaid Services on issues related to clinical diagnostic laboratory tests. DATES: Meeting Dates: The virtual meeting of the Panel is scheduled for Wednesday, July 19, 2023 from 9:00 a.m. to 5:00 p.m., Eastern Daylight Time (E.D.T.) and Thursday, July 20, 2023, from 9:00 a.m. to 5:00 p.m., E.D.T. The Panel is also expected to virtually participate in the Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting for Calendar Year (CY) 2024 on Thursday June 22, 2023 in order to gather information and ask questions to presenters. Notice of the CLFS Annual Public Meeting for CY 2024 is published elsewhere in this issue of the Federal Register. Deadline for Meeting Registration: All stand-by speakers for the Panel meeting must register electronically to our CDLT Panel dedicated email box, CDLTPanel@ cms.hhs.gov by June 1, 2023. Registration is not required for nonspeakers. The public may view this meeting via webinar, or listen-only via teleconference. Webinar and Teleconference Meeting Information: Teleconference dial-in instructions, and related webinar details will be posted on the meeting agenda, which will be available on the CMS website approximately 2 weeks prior to the meeting at https://www.cms.gov/ Regulations-and-Guidance/Guidance/ FACA/AdvisoryPanelonClinical DiagnosticLaboratoryTests.html. A preliminary agenda is described in section II of this notice. ADDRESSES: The Panel meeting will be held virtually and will not occur at the campus of the Centers for Medicare & ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 17:45 Apr 13, 2023 Jkt 259001 Medicaid Services (CMS), Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. FOR FURTHER INFORMATION CONTACT: The CLFS Policy Team via email, CDLTPanel@cms.hhs.gov; or Rasheeda Arthur, (410) 786–3434. The CMS Press Office, for press inquiries, (202) 690– 6145. SUPPLEMENTARY INFORMATION: I. Background The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (CDLTs) (the Panel) is authorized by section 1834A(f)(1) of the Social Security Act (the Act) (42 U.S.C. 1395m–1), as established by section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113–93), enacted on April 1, 2014. The Panel is subject to the Federal Advisory Committee Act (FACA), as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory panels. Section 1834A(f)(1) of the Act directs the Secretary of the Department of Health and Human Services (the Secretary) to consult with an expert outside advisory panel established by the Secretary, composed of an appropriate selection of individuals with expertise in issues related to clinical diagnostic laboratory tests, which may include the development, validation, performance, and application of such tests. Such individuals may include molecular pathologists, researchers, and individuals with expertise in laboratory science or health economics. The Panel will provide input and recommendations to the Secretary and the Administrator of the Centers for Medicare & Medicaid Services (CMS), on the following: • The establishment of payment rates under section 1834A of the Act for new clinical diagnostic laboratory tests, including whether to use ‘‘crosswalking’’ or ‘‘gapfilling’’ processes to determine payment for a specific new test. • The factors used in determining coverage and payment processes for new clinical diagnostic laboratory tests. • Other aspects of the payment system under section 1834A of the Act. A notice announcing the establishment of the Panel and soliciting nominations for members was published in the October 27, 2014 Federal Register (79 FR 63919 through 63920). In the August 7, 2015 Federal Register (80 FR 47491), we announced membership appointments to the Panel along with the first public meeting date PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 for the Panel, which was held on August 26, 2015. Subsequent meetings of the Panel and membership appointments were also announced in the Federal Register. II. Agenda The Agenda for the July 19 and July 20, 2023 Panel meeting will provide for discussion and comment on the following topics as designated in the Panel’s charter: • Calendar Year (CY) 2024 Clinical Laboratory Fee Schedule (CLFS) new and reconsidered test codes, which will be posted on the CMS website at https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ClinicalLab FeeSched/Laboratory_Public_ Meetings.html. • Other CY 2024 CLFS issues designated in the Panel’s charter and further described on our Agenda. A detailed Agenda will be posted approximately 2 weeks before the meeting, on the CMS website at https:// www.cms.gov/Regulations-andGuidance/Guidance/FACA/Advisory PanelonClinicalDiagnosticLaboratory Tests.html. The Panel will make recommendations to the Secretary and the Administrator of CMS regarding crosswalking and gapfilling for new and reconsidered laboratory tests discussed during the CLFS Annual Public Meeting for CY 2024. The Panel will also provide input on other CY 2024 CLFS issues that are designated in the Panel’s charter and specified on the meeting agenda. III. Meeting Participation This meeting is open to the public. Stand-by speakers may participate in the meeting via teleconference and webinar. A stand-by speaker is an individual who will speak on behalf of a company or organization if the Panel has any questions during the meeting about technical information described in the public comments or presentation previously submitted or presented by the organization or company at the recent CLFS Annual Public Meeting for CY 2023 on June 22, 2023. The public may also view or listen-only to the meeting via teleconference and webinar. IV. Registration Instructions for Standby Speakers Beginning May 1, 2023 and ending June 27, 2023 at 5:00 p.m. E.D.T., registration to serve as a stand-by speaker may be completed by sending an email to the following resource box CDLTPanel@cms.hhs.gov. The subject of the email should state ‘‘Stand-by Speaker Registration for CDLT Panel Meeting.’’ In the email, all of the E:\FR\FM\14APN1.SGM 14APN1 Federal Register / Vol. 88, No. 72 / Friday, April 14, 2023 / Notices following information must be submitted when registering: • Stand-by Speaker name. • Organization or company name. • Email addresses that will be used by the speaker in order to connect to the virtual meeting. • New or Reconsidered Code (s) for which the company or organization you are representing submitted a comment or presentation. Registration details may not be revised once they are submitted. If registration details require changes, a new registration entry must be submitted by the date specified in the DATES section of this notice. Additionally, registration information must reflect individual- level content and not reflect an organization entry. Also, each individual may only register one person at a time. That is, one individual may not register multiple individuals at the same time. After registering, a confirmation email will be sent upon receipt of the registration. The email will provide information to the speaker in preparation for the meeting. Registration is only required for stand-by speakers and must be submitted by the deadline specified in the DATES section of this notice. Note: No registration is required for participants who plan to view the Panel meeting via webinar or listen via teleconference. V. Panel Recommendations and Discussions The Panel’s recommendations will be posted approximately 2 weeks after the meeting on the CMS website at https:// www.cms.gov/Regulations-andGuidance/Guidance/FACA/Advisory PanelonClinicalDiagnosticLaboratory Tests.html. VI. Special Accommodations Individuals viewing or listening to the meeting who are hearing or visually impaired and have special requirements, or a condition that requires special assistance, should send an email to the resource box (CDLTPanel@cms.hhs.gov). The deadline for submitting this request is listed in the DATES section of this notice. ddrumheller on DSK120RN23PROD with NOTICES1 VII. Copies of the Charter The Secretary’s Charter for the Medicare Advisory Panel on CDLT’s is available on the CMS website at https:// cms.gov/Regulations-and-Guidance/ Guidance/FACA/Advisory PanelonClinicalDiagnosticLaboratory Tests.html or you may obtain a copy of the charter by submitting a request to the contact listed in the FOR FURTHER VerDate Sep<11>2014 17:45 Apr 13, 2023 Jkt 259001 INFORMATION CONTACT section of this notice. VIII. Collection of Information Requirements This document does not impose information collection requirements, that is, reporting, recordkeeping or third-party disclosure requirements. Consequently, there is no need for review by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.). The Administrator of CMS, Chiquita Brooks-LaSure, having reviewed and approved this document, authorizes Evell J. Barco Holland, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the Federal Register. Dated: April 11, 2023. Evell J. Barco Holland, Federal Register Liaison, Centers for Medicare & Medicaid Services. [FR Doc. 2023–07913 Filed 4–13–23; 8:45 am] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–1796–N] Medicare Program; Public Meeting on June 22, 2023 Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 2024 Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice. AGENCY: This notice announces a public meeting to receive comments and recommendations (including data on which recommendations are based) on the appropriate basis for establishing payment amounts for new or substantially revised Healthcare Common Procedure Coding System codes being considered for Medicare payment under the Clinical Laboratory Fee Schedule for calendar year 2024. This meeting also provides a forum for those who submitted certain reconsideration requests regarding final determinations made last year on new test codes and for the public to provide comment on the requests. DATES: CLFS Annual Public Meeting Date: The virtual meeting is scheduled for SUMMARY: PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 23085 Thursday, June 22, 2023 from 9:00 a.m. to 5:00 p.m., E.D.T. Deadline for Submission of Presentations and Written Comments: All presenters for the CLFS Annual Public Meeting must register and submit their presentations electronically to our CLFS dedicated email box, CLFS_ Annual_Public_Meeting@cms.hhs.gov, by June 1, 2023 at 5:00 p.m., E.D.T. All written comments (non-presenter comments) must also be submitted electronically to our CLFS dedicated email box, CLFS_Annual_Public_ Meeting@cms.hhs.gov, by June 1, 2023, at 5:00 p.m., E.D.T. Any presentations or written comments received after that date and time will not be included in the meeting and will not be reviewed. Deadline for Submitting Requests for Special Accommodations: Requests for special accommodations must be received no later than June 1, 2023 at 5:00 p.m. E.D.T. Publication of Proposed Determinations: We intend to publish our proposed determinations for new test codes and our proposed determinations for reconsidered codes (as described later in section II, ‘‘Format’’ of this notice) for CY 2024 by early September 2023. Deadline for Submission of Written Comments Related to Proposed Determinations: Comments in response to the proposed determinations will be due by early October 2023. ADDRESSES: The CLFS Annual Public Meeting will be held virtually and will not occur at the campus of the Centers for Medicare & Medicaid Services (CMS), Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244– 1850. Where to Submit Written Comments: Interested parties should submit all written comments on presentations and proposed determinations electronically to our CLFS dedicated email box, CLFS_ Annual_Public_Meeting@cms.hhs.gov (the specific date for the publication of these determinations and the deadline for submitting comments regarding these determinations will be published on the CMS website). FOR FURTHER INFORMATION CONTACT: The CLFS Policy Team and submit all inquiries to the CLFS dedicated email box, CLFS_Annual_Public_Meeting@ cms.hhs.gov with the subject entitled ‘‘CLFS Annual Public Meeting Inquiry.’’ SUPPLEMENTARY INFORMATION: I. Background Section 531(b) of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106–554) required E:\FR\FM\14APN1.SGM 14APN1

Agencies

[Federal Register Volume 88, Number 72 (Friday, April 14, 2023)]
[Notices]
[Pages 23084-23085]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-07913]



[[Page 23084]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS-1797-N]


Medicare Program; Meeting Announcement for the Medicare Advisory 
Panel on Clinical Diagnostic Laboratory Tests

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces the public meeting dates for the 
Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the 
Panel) on Wednesday, July 19, 2023 and Thursday, July 20, 2023. The 
purpose of the Panel is to advise the Secretary of the Department of 
Health and Human Services and the Administrator of the Centers for 
Medicare & Medicaid Services on issues related to clinical diagnostic 
laboratory tests.

DATES: Meeting Dates: The virtual meeting of the Panel is scheduled for 
Wednesday, July 19, 2023 from 9:00 a.m. to 5:00 p.m., Eastern Daylight 
Time (E.D.T.) and Thursday, July 20, 2023, from 9:00 a.m. to 5:00 p.m., 
E.D.T. The Panel is also expected to virtually participate in the 
Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting for 
Calendar Year (CY) 2024 on Thursday June 22, 2023 in order to gather 
information and ask questions to presenters. Notice of the CLFS Annual 
Public Meeting for CY 2024 is published elsewhere in this issue of the 
Federal Register.
    Deadline for Meeting Registration: All stand-by speakers for the 
Panel meeting must register electronically to our CDLT Panel dedicated 
email box, [email protected] by June 1, 2023. Registration is not 
required for non-speakers. The public may view this meeting via 
webinar, or listen-only via teleconference.
    Webinar and Teleconference Meeting Information: Teleconference 
dial-in instructions, and related webinar details will be posted on the 
meeting agenda, which will be available on the CMS website 
approximately 2 weeks prior to the meeting at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/
AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html. A preliminary 
agenda is described in section II of this notice.

ADDRESSES: The Panel meeting will be held virtually and will not occur 
at the campus of the Centers for Medicare & Medicaid Services (CMS), 
Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244-
1850.

FOR FURTHER INFORMATION CONTACT: The CLFS Policy Team via email, 
[email protected]; or Rasheeda Arthur, (410) 786-3434. The CMS 
Press Office, for press inquiries, (202) 690-6145.

SUPPLEMENTARY INFORMATION:

I. Background

    The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests 
(CDLTs) (the Panel) is authorized by section 1834A(f)(1) of the Social 
Security Act (the Act) (42 U.S.C. 1395m-1), as established by section 
216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 
113-93), enacted on April 1, 2014. The Panel is subject to the Federal 
Advisory Committee Act (FACA), as amended (5 U.S.C. Appendix 2), which 
sets forth standards for the formation and use of advisory panels.
    Section 1834A(f)(1) of the Act directs the Secretary of the 
Department of Health and Human Services (the Secretary) to consult with 
an expert outside advisory panel established by the Secretary, composed 
of an appropriate selection of individuals with expertise in issues 
related to clinical diagnostic laboratory tests, which may include the 
development, validation, performance, and application of such tests. 
Such individuals may include molecular pathologists, researchers, and 
individuals with expertise in laboratory science or health economics.
    The Panel will provide input and recommendations to the Secretary 
and the Administrator of the Centers for Medicare & Medicaid Services 
(CMS), on the following:
     The establishment of payment rates under section 1834A of 
the Act for new clinical diagnostic laboratory tests, including whether 
to use ``crosswalking'' or ``gapfilling'' processes to determine 
payment for a specific new test.
     The factors used in determining coverage and payment 
processes for new clinical diagnostic laboratory tests.
     Other aspects of the payment system under section 1834A of 
the Act.
    A notice announcing the establishment of the Panel and soliciting 
nominations for members was published in the October 27, 2014 Federal 
Register (79 FR 63919 through 63920). In the August 7, 2015 Federal 
Register (80 FR 47491), we announced membership appointments to the 
Panel along with the first public meeting date for the Panel, which was 
held on August 26, 2015. Subsequent meetings of the Panel and 
membership appointments were also announced in the Federal Register.

II. Agenda

    The Agenda for the July 19 and July 20, 2023 Panel meeting will 
provide for discussion and comment on the following topics as 
designated in the Panel's charter:
     Calendar Year (CY) 2024 Clinical Laboratory Fee Schedule 
(CLFS) new and reconsidered test codes, which will be posted on the CMS 
website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html.
     Other CY 2024 CLFS issues designated in the Panel's 
charter and further described on our Agenda.
    A detailed Agenda will be posted approximately 2 weeks before the 
meeting, on the CMS website at https://www.cms.gov/Regulations-and-
Guidance/Guidance/FACA/
AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html. The Panel will 
make recommendations to the Secretary and the Administrator of CMS 
regarding crosswalking and gapfilling for new and reconsidered 
laboratory tests discussed during the CLFS Annual Public Meeting for CY 
2024. The Panel will also provide input on other CY 2024 CLFS issues 
that are designated in the Panel's charter and specified on the meeting 
agenda.

III. Meeting Participation

    This meeting is open to the public. Stand-by speakers may 
participate in the meeting via teleconference and webinar. A stand-by 
speaker is an individual who will speak on behalf of a company or 
organization if the Panel has any questions during the meeting about 
technical information described in the public comments or presentation 
previously submitted or presented by the organization or company at the 
recent CLFS Annual Public Meeting for CY 2023 on June 22, 2023. The 
public may also view or listen-only to the meeting via teleconference 
and webinar.

IV. Registration Instructions for Stand-by Speakers

    Beginning May 1, 2023 and ending June 27, 2023 at 5:00 p.m. E.D.T., 
registration to serve as a stand-by speaker may be completed by sending 
an email to the following resource box [email protected]. The 
subject of the email should state ``Stand-by Speaker Registration for 
CDLT Panel Meeting.'' In the email, all of the

[[Page 23085]]

following information must be submitted when registering:
     Stand-by Speaker name.
     Organization or company name.
     Email addresses that will be used by the speaker in order 
to connect to the virtual meeting.
     New or Reconsidered Code (s) for which the company or 
organization you are representing submitted a comment or presentation.
    Registration details may not be revised once they are submitted. If 
registration details require changes, a new registration entry must be 
submitted by the date specified in the DATES section of this notice. 
Additionally, registration information must reflect individual- level 
content and not reflect an organization entry. Also, each individual 
may only register one person at a time. That is, one individual may not 
register multiple individuals at the same time.
    After registering, a confirmation email will be sent upon receipt 
of the registration. The email will provide information to the speaker 
in preparation for the meeting. Registration is only required for 
stand-by speakers and must be submitted by the deadline specified in 
the DATES section of this notice. Note: No registration is required for 
participants who plan to view the Panel meeting via webinar or listen 
via teleconference.

V. Panel Recommendations and Discussions

    The Panel's recommendations will be posted approximately 2 weeks 
after the meeting on the CMS website at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/
AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html.

VI. Special Accommodations

    Individuals viewing or listening to the meeting who are hearing or 
visually impaired and have special requirements, or a condition that 
requires special assistance, should send an email to the resource box 
([email protected]). The deadline for submitting this request is 
listed in the DATES section of this notice.

VII. Copies of the Charter

    The Secretary's Charter for the Medicare Advisory Panel on CDLT's 
is available on the CMS website at https://cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html or you may obtain 
a copy of the charter by submitting a request to the contact listed in 
the FOR FURTHER INFORMATION CONTACT section of this notice.

VIII. Collection of Information Requirements

    This document does not impose information collection requirements, 
that is, reporting, recordkeeping or third-party disclosure 
requirements. Consequently, there is no need for review by the Office 
of Management and Budget under the authority of the Paperwork Reduction 
Act of 1995 (44 U.S.C. 3501 et seq.).
    The Administrator of CMS, Chiquita Brooks-LaSure, having reviewed 
and approved this document, authorizes Evell J. Barco Holland, who is 
the Federal Register Liaison, to electronically sign this document for 
purposes of publication in the Federal Register.

    Dated: April 11, 2023.
Evell J. Barco Holland,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2023-07913 Filed 4-13-23; 8:45 am]
BILLING CODE 4120-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.